A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenics.
J Clin Psychopharmacol
; 9(3): 209-12, 1989 Jun.
Article
en En
| MEDLINE
| ID: mdl-2567742
A dose-finding study of proglumide added to neuroleptics for the treatment of schizophrenic patients who were relatively refractory to their ongoing neuroleptic regimen was performed. Initially, four patients were open-label treated using a regimen of progressively increasing doses (proglumide 0.5-1024 mg/day) for 4 weeks. Afterwards, seven patients were given low doses (0.5 mg/day) followed by higher doses (500 mg/day) for a total period of 8 weeks. Overall, no improvement was seen in these refractory patients as a group at any dose. In individual patients, modest improvement or worsening of psychotic symptoms was observed. The results suggest that more potent cholecystokinin (CCK) antagonists and a greater knowledge of CCK pharmacology are needed before novel treatments exploiting the interaction of CCK and dopamine in the brain can be developed.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Proglumida
/
Esquizofrenia
/
Psicología del Esquizofrénico
/
Glutamina
Límite:
Humans
Idioma:
En
Revista:
J Clin Psychopharmacol
Año:
1989
Tipo del documento:
Article
Pais de publicación:
Estados Unidos